GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Loans Receivable

PBM (Psyence Biomedical) Loans Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Loans Receivable?

Psyence Biomedical's Loans Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Psyence Biomedical Loans Receivable Historical Data

The historical data trend for Psyence Biomedical's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Loans Receivable Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Loans Receivable
- - - -

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Loans Receivable Get a 7-Day Free Trial - - - - -

Psyence Biomedical Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Psyence Biomedical Loans Receivable Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical Business Description

Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.